Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Parkinson's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Parkinson's
    TopAbstracts in Parkinson's 07/01/2009 - (DGNews)
    Long-Term Use of Prolonged-Release Ropinirole Well Tolerated by Patients With Early or Advanced Parkinson's Disease: Presented at ENS - (DGDispatch)
    Patients Treated With Preladenant for Parkinson's Disease Experience Reduced "Off" Time and Increased "On" Time With No Increase in Dyskinesia: Presented at MDS - (DGDispatch)
    Istradefylline Well Tolerated, Improves Motor Function During "On" State in Patients Receiving Levodopa for Parkinson's Disease: Presented at MDS - (DGDispatch)
    Zonisamide Safe and Effective in Long-Term Treatment of Parkinson's Disease: Presented at MDS - (DGDispatch)

    News archive

     Recent webcasts/CME - Parkinson's
      Initiating and Monitoring Pharmacotherapy in Patients with Parkinson's Disease
      Effective Management in Early Idiopathic Parkinson's Disease
      Case Studies in the Advancement of Parkinson's Disease
      Early Versus Delayed Diagnosis and Treatment of Parkinson's Disease: What You Need to Know
      Managing Parkinson's Disease with Continuous Dopaminergic Stimulation

      Webcasts/CME archive

       Recent cases - Parkinson's
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        Development of Parkinsonism Following Exposure to Aripiprazole: Two Case Reports
        Hypothermia with Osborn Waves in Parkinson's Disease
        HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
        Gliomatosis Cerebri Presenting as Rapidly Progressive Dementia and Parkinsonism in an Elderly Woman: A Case Report

        Cases archive
          




        my personal edition > parkinson's > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Istradefylline Improves Motor Function in Parkinson's Patients Experiencing "Off" Time: Presented at AAN

          By Maria Bishop

          BOSTON, MA -- May 7, 2007 -- Istradefylline, a novel adenosine A2A receptor antagonist, appears to reduce the wearing-off time associated with levodopa and other anti-Parkinson's medications when administered at 20 mg/day to Parkinson's patients, according to results of a multicenter, phase 3, double-blind, efficacy study.

          A reduction of "off" time means improved motor function for patients experiencing motor complications, said the researcher who reported these findings here at the American Academy of Neurology (AAN) 59th Annual Meeting.

          Joel M. Trugman, MD, associate professor of neurology, department of neurology, University of Virginia, Charlottesville, Virginia, led the study, in which 115 patients randomly received istradefylline 20 mg/day while 115 received matched placebo. All patients were taking stable doses of levodopa; other anti-Parkinson's medications were also in use, to varying degrees.

          Nearly 90% of patients in each group completed the 12-week study.

          At the endpoint, the change from baseline in the percentage of awake time per day spent in the "off" state was -9.49% for istradefylline and -4.92% for placebo. The difference between the groups was significant (4.57%; P =.025), and translates to an average of 44 minutes less in "off" time for the treatment group.

          Similar frequencies were seen in each group of treatment-emergent adverse events, serious adverse events, and discontinuation due to adverse events. Safety was assessed by reporting adverse events and monitoring of vital signs, weight, laboratory tests, electrocardiogram, and clinical examinations.

          The authors noted that dyskinesia was more frequent (+9.4%) in the istradefylline group than in the placebo group.

          This study was supported by Kyowa Pharmaceutical Inc.


          [Presentation title: Primary Efficacy and Safety of Istradefylline (KW-6002) in Levodopa-Treated Parkinsons Disease Patients With Motor Response Complications: Results of the KW-6002-US-013 Study. Abstract P06.023]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send